A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Bliss, Carly MFreyn, Alec W
Caniels, Tom G
Leyva-Grado, Victor H
Nachbagauer, Raffael
Sun, Weina
Tan, Gene S
Gillespie, Virginia L
McMahon, Meagan
Krammer, Florian
Hill, Adrian V S
Palese, Peter
Coughlan, Lynda
Date
2022-01-07Journal
Molecular TherapyPublisher
ElsevierType
Article
Metadata
Show full item recordAbstract
Conventional influenza vaccines fail to confer broad protection against diverse influenza A viruses with pandemic potential. Efforts to develop a universal influenza virus vaccine include refocusing immunity towards the highly conserved stalk domain of the influenza virus surface glycoprotein, hemagglutinin (HA). We constructed a non-replicating adenoviral (Ad) vector, encoding a secreted form of H1 HA, to evaluate HA stalk-focused immunity. The Ad5_H1 vaccine was tested in mice for its ability to elicit broad, cross-reactive protection against homologous, heterologous, and heterosubtypic lethal challenge in a single-shot immunization regimen. Ad5_H1 elicited hemagglutination inhibition (HI+) active antibodies (Abs), which conferred 100% sterilizing protection from homologous H1N1 challenge. Furthermore, Ad5_H1 rapidly induced H1-stalk-specific Abs with Fc-mediated effector function activity, in addition to stimulating both CD4+ and CD8+ stalk-specific T cell responses. This phenotype of immunity provided 100% protection from lethal challenge with a head-mismatched, reassortant influenza virus bearing a chimeric HA, cH6/1, in a stalk-mediated manner. Most importantly, 100% protection from mortality following lethal challenge with a heterosubtypic avian influenza virus, H5N1, was observed following a single immunization with Ad5_H1. In conclusion, Ad-based influenza vaccines can elicit significant breadth of protection in naive animals and could be considered for pandemic preparedness and stockpiling.Rights/Terms
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.Keyword
adenoviraladenovirus
hemagglutinin
heterosubtypic
immunogenicity
influenza
stalk
stem
universal vaccine
vaccine
vector
Identifier to cite or link to this item
http://hdl.handle.net/10713/17884ae974a485f413a2113503eed53cd6c53
10.1016/j.ymthe.2022.01.011
Scopus Count
Collections
Related articles
- Characterization of Immune Response towards Generation of Universal Anti-HA-Stalk Antibodies after Immunization of Broiler Hens with Triple H5N1/NA-HA-M1 VLPs.
- Authors: Gromadzka B, Chraniuk M, Hovhannisyan L, Uranowska K, Szewczyk B, Narajczyk M, Panasiuk M
- Issue date: 2022 Mar 30
- Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
- Authors: Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F
- Issue date: 2014 Nov
- H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
- Authors: Carreño JM, Strohmeier S, Kirkpatrick Roubidoux E, Hai R, Palese P, Krammer F
- Issue date: 2020 Dec 15
- Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for <i>In Vivo</i> Protection in a Serum Transfer Mouse Challenge Model.
- Authors: Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, Palese P, Krammer F, Nachbagauer R
- Issue date: 2017 Sep 19
- Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
- Authors: Kim EH, Park HJ, Han GY, Song MK, Pereboev A, Hong JS, Chang J, Byun YH, Seong BL, Nguyen HH
- Issue date: 2014 Sep 1